|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 42.9 CNY | +5.07% |
|
+1.66% | -20.11% |
| Mar. 28 | Beijing Tongrentang Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Mar. 06 | China Approves Tong Ren Tang Group's Clinical Trial of Heart Failure Drug | MT |
Beijing Tongrentang Co., Ltd reported earnings results for the nine months ended September 30, 2022. For the nine months, the company reported sales was CNY 10,900.28 million compared to CNY 10,683.18 million a year ago. Revenue was CNY 10,900.28 million compared to CNY 10,683.18 million a year ago.
Net income was CNY 1,002.87 million compared to CNY 920 million a year ago. Basic earnings per share from continuing operations was CNY 0.731 compared to CNY 0.671 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| -20.11% | 8.12B | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
BEIJING TONGRENTANG CO., LTD 
